IL23A and inflammatory bowel disease: However, given that a certain proportion of AS patients lack gut inflammation and are resistant to treatment with IL-23 blockade, which is effective for IBD treatment, the pathogenesis of AS also appears to exhibit substantial heterogeneity [149].